Brief: Pds Biotech Announces Final Topline Survival Data From Versatile-002 Phase 2 Trial In Head And Neck Cancer
25/08/2025 13:44
Aug 25 (Reuters) - PDS Biotechnology Corp PDSB.O: PDS BIOTECH ANNOUNCES FINAL TOPLINE SURVIVAL DATA FROM VERSATILE-002 PHASE 2 TRIAL IN HEAD AND NECK CANCER PDS BIOTECHNOLOGY CORP - MEDIAN OVERALL SURVIVAL OF 39.3 MONTHS IN CPS ≥ 1 PATIENTS PDS BIOTECHNOLOGY CORP - VERSATILE-003 PHASE 3 TRIAL IN PROGRESS Source text: ID:nGNX3VvbCw Further company coverage: PDSB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing